1. Regeneron faces disappointing sales and legal challenges affecting EYLEA sales. 2. Analysts have downgraded REGN's price target amid increased competition.
The downgrade from TD Cowen suggests a negative outlook on revenue, similar to past downgrades that affected stock prices significantly.
Sales figures and analyst views are crucial for REGN's financial health, impacting investor sentiment and stock performance.
Immediate effects from analyst downgrades usually impact stocks quickly, historically observed in previous cases of downgrades.